Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
ConclusionIpragliflozin was effective and well tolerated in Japanese patients with T2DM over 12 months in the real-world clinical setting. Improvements in liver function parameters (AST and ALT) were observed in T2DM patients with abnormal liver function.Trial RegistrationClinicalTrials.gov identifier, NCT02479399.FundingAstellas Pharma Inc., Japan.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fatty Liver Disease (FLD) | Japan Health | Liver | Pharmaceuticals | Statistics | Study | Urology & Nephrology